for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma

March 14 (Reuters) - Merck & Co Inc

* FDA approves Merck’s Keytruda® (pembrolizumab) for adult and pediatric patients with classical hodgkin lymphoma (chl) refractory to treatment, or who have relapsed after three or more prior lines of therapy

* Merck & Co - FDA has approved keytruda for treatment of adult and pediatric patients with refractory classical hodgkin lymphoma Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up